Non-Small Cell Lung Cancer: Biomarker-Based Diagnosis and Therapy

Biomarker-based diagnosis and therapy of lung cancer have revolutionized treatment strategies by enabling personalized medicine. Biomarkers such as EGFR mutations, ALK rearrangements, and PD-L1 expression levels are crucial in guiding diagnostic tests and therapeutic decisions. They allow for early detection, accurate prognosis, and selection of targeted therapies tailored to individual patients, improving treatment outcomes and minimizing side effects. In diagnostics, biomarkers aid in distinguishing between different types and stages of lung cancer, facilitating timely intervention. Therapeutically, they inform decisions on whether to use targeted therapies like tyrosine kinase inhibitors or immunotherapies, which can selectively attack cancer cells while sparing healthy tissue. The ongoing research in identifying new biomarkers promises further advancements in precision medicine, offering hope for more effective and personalized treatment options for lung cancer patients. This book traces the progress of this field and highlights some of its key concepts and applications. Also included in this book is a detailed explanation of the various biomarker-based diagnosis and therapy of lung cancer. Students, researchers, experts and all associated with oncology will benefit alike from this book.